San Diego-based mostly Viking Therapeutics marked alone as a significant competitor during the weight loss drug marketplace in February following revealing promising facts from a mid-phase trial of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when offered to be a weekly injection and in March the co